New monitoring system could be ‘the future’ of diabetes control
Patients with type 1 diabetes who used the “smart” Guardian Connect continuous glucose monitoring (CGM) system and Sugar.IQ app improved their glycemic control in a short pilot study.
Both products are creations of Medtronic.
Overall, patients increased time spent in the normal glucose range by 30 minutes a day, said Huzefa Neemuchwala, PhD, MBA, head of Innovation, Data & Informatics, Medtronic Diabetes Group, in Northridge, CA during an oral presentation here at the American Diabetes Association (ADA) 2018 Scientific Sessions.
The United States Food and Drug Administration (FDA) approved the Guardian Connect CGM earlier this year, making it the first to launch in the United Sates with a smartphone-only platform. The Sugar.IQ app will use artificial intelligence technology to pull data from the Guardian Connect and combine with additional information.
The app continually analyzes how an individual’s glucose levels respond to food intake, insulin dosages, daily routines, and other factors, so it reveals patterns that can help people with diabetes keep their glucose levels in target range.
“I think it’s the future,” session chair Anders L. Carlson, MD, Medical Director, International Diabetes Center, and Assistant Professor, University of Minnesota Medical School, Minneapolis, told Medscape Medical News.
Everyone eventually will be moving towards more smartphone-based apps and will want to use apps to manage their diabetes, he said.